Local application of prostaglandin E2 reduces trap, calcitonin receptor and metalloproteinase-2 immunoreactivity in the rat periodontium.
It has been shown that prostaglandin E2 (PGE2) locally released adjacent to the mandible over a 20-day period increases alveolar bone area, in part, due to a reduction in the percentage of eroded surface. To determine the effect of PGE2 on alveolar bone resorption, left mandibles from 24 Lewis rats were treated over a 20-day period with a local application of PGE2 (0.1, 0.05 or 0.025 mg/day) or placebo. The right side served as the non-treated matched control. Tissue sections were stained for tartrate resistant acid phosphatase (TRAP) calcitonin receptor (CTR) and metalloproteinase-2 (MMP-2). Matched samples were analysed by Wilcoxon matched pairs test and, a non-parametric one-way analysis of variance compared groups of treatment. Those tissues treated with PGE2 at doses of 0.1 and 0.05 mg/day showed significantly reduced numbers of TRAP and CTR-positive multinucleated cells compared with matched controls (p<0.005), as well as significantly reduced numbers of TRAP- and CTR-positive multinucleated cells when compared with the placebo-treated group (p<0.001). The number of periodontal ligament cells expressing MMP-2 was also significantly reduced in tissues treated with the two higher doses of PGE2 (p<0.001) comparing with both matched controls and the placebo-treated group. Following a 20-day period, locally released PGE2 at doses of 0.1 and 0.05 mg/day appears to affect alveolar bone resorption in the periodontium of rats, as the number of multinucleated cells expressing TRAP and CTR are significantly reduced. Furthermore, the same doses of PGE2 also significantly reduced the expression of MMP-2 by the periodontal cells.
Ramirez-Yañez
G O
GO
Oral Biology and Pathology, School of Dentistry, The University of Queensland, 5th Floor, St. Lucia Campus, Brisbane, Qld 4072, Australia. g.ramirez@uq.edu.au
Seymour
G J
GJ
Symons
A L
AL
D000135:Acid Phosphatase / Q000032:analysis / Q000378:metabolism*; D016301:Alveolar Bone Loss / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy / Q000378:metabolism; D002452:Cell Count; D015232:Dinoprostone / Q000494:pharmacology*; D005260:Female; D007150:Immunohistochemistry / Q000379:methods; D007527:Isoenzymes / Q000032:analysis / Q000378:metabolism*; D008336:Mandibular Diseases / Q000378:metabolism / Q000473:pathology; D020778:Matrix Metalloproteinase 2 / Q000032:analysis / Q000378:metabolism*; D010519:Periodontium / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D018003:Receptors, Calcitonin / Q000032:analysis / Q000378:metabolism*; D000071681:Tartrate-Resistant Acid Phosphatase
D007527:Isoenzymes; D018003:Receptors, Calcitonin; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D020778:Matrix Metalloproteinase 2; D015232:Dinoprostone